An Overview of a Practice-Changing Trial With mFOLFIRINOX in Pancreatic Cancer
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX (mFOLFIRINOX) regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
While gemcitabine has been the standard of care since 2008, a mFOLFIRINOX regimen of fluorouracil (5-FU), oxaliplatin, leucovorin, and irinotecan was developed in France to show superiority. While it was superior to gemcitabine in metastatic disease, it was still too toxic for use in the adjuvant setting.
Bolus 5-FU is suppressed in the mFOLFIRINOX regimen and instead continuous infusion of 5-FU is used with the other agents. In this trial, mFOLFIRINOX was compared to gemcitabine in patients 3 to 12 weeks after surgery for 6 months.
See more information on thispractice-changing trial in pancreatic cancer and the results
Phase 1b/2 Study of BXQ-350 in Metastatic Colorectal Cancer Completes Enrollment
November 27th 2024Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.
Read More
